RecruitingPhase 2NCT06016634

Alendronate for Osteonecrosis in Adults With Sickle Cell Disease

A Feasibility Study of Alendronate as Treatment for Osteonecrosis in Adults With Sickle Cell Disease


Sponsor

University of California, Davis

Enrollment

30 participants

Start Date

Feb 9, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

A prospective, single-arm, intervention study of oral alendronate in adults with sickle cell disease and osteonecrosis


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria4

  • Age 18-80 years with SCD (any genotype, confirmed by hemoglobin electrophoresis or high performance liquid chromatography)
  • Ability to provide written informed consent
  • Ability to lay on a dual-energy X-ray absorptiometry (DXA) scanner
  • Negative urine pregnancy test for anyone of childbearing potential at study entry

Exclusion Criteria5

  • Pregnant women
  • Adults unable to consent
  • Individuals who are not yet adults (infants, children, teenagers)
  • Prisoners
  • Hospitalizations (for any cause) within 2 weeks of study entry

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAlendronate Sodium

Administer oral alendronate 70 mg once a week x 24 weeks to all study participants


Locations(1)

UC Davis Comprehensive Cancer Center

Sacramento, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06016634


Related Trials